Clinical Trials of Influenza Vaccines: Special Challenges

Methods in Molecular Biology
Adam Finn

Abstract

Clinical trials of vaccines differ from those of drugs both practically and ethically. Influenza vaccine trials pose additional challenges which flow from the seasonality of the disease and vaccine programmes and the changeability of circulating strains and epidemic size. Serological correlates are widely used in evaluating influenza vaccines but interpreting such responses is also difficult. Development and testing of vaccines for deployment in an influenza pandemic combines all these obstacles with extreme unpredictability, enormous urgency and the need for very large numbers of doses. Advances in manufacturing technology, diagnostics, identification of stable protective antigens and epitopes, new adjuvants and improved understanding of indirect and downstream effects may help to alleviate these difficulties in the future.

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Related Papers

BMJ : British Medical Journal
John M Watson, Richard G Pebody
The Lancet Infectious Diseases
Iain StephensonYuri Pervikov
Journal of the American Pharmacists Association : JAPhA
Youqi Zhang, Mary S Hayney
Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
Lars R Haaheim
© 2022 Meta ULC. All rights reserved